ArticlemSphere2023
A Novel
Article in mSphere, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 17 citations in OpenAlex.
- Protective immunity againstmSphere · 2026Article
- Development of a NovelVaccines · 2026Article
- Compatibility and Stability of aVaccines · 2025Article
- A multifunctional anti-O-Antigen human monoclonal antibody protects againstProceedings of the National Academy of Sciences of the United States of America · 2025Article
- Protein-specific immune response elicited by themSphere · 2025Article
- Conserved antigens for enteric vaccines.Vaccine · 2025Review
- A broad spectrum Shigella vaccine based on VirGNPJ vaccines · 2025Article
- Structural and Serological Characterization of Yet Another New O Antigen, O86, inInternational journal of molecular sciences · 2024Article
- A multi-epitope protein vaccine encapsulated in alginate nanoparticles as a candidate vaccine against Shigella sonnei.Scientific reports · 2024Article
- Evaluation of a QuadrivalentVaccines · 2024Article
- Review
- Exploring Natural Immune Responses toOpen forum infectious diseases · 2024Article
- Shigella virulence protein VirG is a broadly protective antigen and vaccine candidate.NPJ vaccines · 2024Article
- Development of a visual Adhesion/Invasion Inhibition Assay to assess the functionality ofFrontiers in immunology · 2024Article
- A candidate glycoconjugate vaccine induces protective antibodies in the serum and intestinal secretions, antibody recall response and memory T cells and protects against both typhoidal and non-typhoidalFrontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.